ArticleStroke (Hoboken, N.J.)2023
Nationwide Trends in Reperfusion Therapy and Outcomes of Acute Ischemic Stroke According to Severity: The Japan Stroke Data Bank.
Article in Stroke (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Thrombolysis in Patients With Mild Ischemic Stroke: A Comparative Effectiveness Study From the Norwegian Stroke Registry.European journal of neurology · 2026Article
- Endovascular Therapy for Acute Ischemic Stroke Beyond 24 Hours After Onset: A Nationwide Registry-Based Analysis.Stroke (Hoboken, N.J.) · 2026Article
- Trends of Intravenous Thrombolysis and Thrombectomy for Low NIHSS Score (<6) Strokes in the United States: A National Inpatient Sample Study.Stroke (Hoboken, N.J.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It is unclear whether all patient subgroups with acute ischemic stroke have benefited from advances in reperfusion therapy. We investigated long-term trends of reperfusion therapy and outcomes according to the stroke severity. Methods: Patients with acute ischemic stroke registered in the prospective nationwide hospital-based registry between 2000 and 2020 were examined. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥10 and ≤5 was considered to indicate possible large vessel occlusions and minor deficits, respectively. Secular changes were assessed per 5-year cohorts (2000-2005, 2006-2010, 2011-2015, 2016-2020). Outcomes included favorable outcome (modified Rankin scale score 0-2 at discharge). Results: Of 127 741 patients, NIHSS score was ≥10 in 31 747 patients (24.9%), 6-9 in 17 083 patients (13.4%), and ≤5 in 78 911 patients (61.8%). In patients with NIHSS score ≥10, intravenous thrombolysis frequency increased from 1.6% to 26.5% between the 2000 to 2005 and 2016 to 2020 cohorts; endovascular therapy frequency increased from 2.0% to 29.8%. Favorable outcomes increased over time (adjusted odds ratio per 1-cohort, 1.254 [95% CI, 1.204-1.306]). In patients with NIHSS score 6-9, intravenous thrombolysis frequency increased from 0.5% to 16.4%, and endovascular therapy frequency increased from 1.1% to 9.0%. Favorable outcomes did not change over time (1.005 [0.966-1.046]). In patients with NIHSS score ≤5, intravenous thrombolysis frequency increased from 0.2% to 5.1%, and endovascular therapy frequency increased from 0.7% to 2.8%. Favorable outcomes decreased over time (0.954 [0.931-0.978]). Conclusions: Use of reperfusion therapy has increased, particularly in patients with NIHSS score ≥10. Favorable outcomes significantly increased over time in patients with NIHSS score ≥10 but decreased in those with NIHSS score ≤5.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.